Stockscreener 앱 받기
0.289
5.82%
0.0159
시간 외 거래:
.28
-0.009
-3.11%
전일 마감가:
$0.2731
열려 있는:
$0.2705
하루 거래량:
138.74K
Relative Volume:
0.25
시가총액:
$27.47M
수익:
$1.22M
순이익/손실:
$-14.15M
주가수익비율:
-1.1115
EPS:
-0.26
순현금흐름:
$-6.55M
1주 성능:
+3.62%
1개월 성능:
+7.08%
6개월 성능:
-38.51%
1년 성능:
+3.96%
1일 변동 폭
$0.2702
$0.289
1주일 범위
$0.265
$0.305
52주 변동 폭
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
명칭
IGC Pharma Inc
전화
301-983-0998
주소
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.289 | 25.95M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
IGC Pharma Inc 주식(IGC)의 최신 뉴스
IGC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IGC Should I Buy - Intellectia AI
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo - PharmiWeb.com
Inside IGC Pharma’s AI push to clean up Alzheimer’s data - Stock Titan
IGC PE Ratio & Valuation, Is IGC Overvalued - Intellectia AI
FOMO Trade: What is the Moat Score of IGC Pharma IncBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Trend Report: What is the Moat Score of IGC Pharma IncJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - The Globe and Mail
Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stockWatch List & Real-Time Sentiment Analysis - baoquankhu1.vn
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance
Analyst lifts IGC Pharma price target to $5 in new research note - Stock Titan
IGC Enhances Alzheimer's Trial with New Clinical Research Collab - GuruFocus
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Weatherford Democrat
Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan
Will IGC Pharma Inc. stock go up in YEARDay Trade & Daily Momentum Trading Reports - mfd.ru
Trend Review: Will IGC Pharma Inc benefit from green energy policiesJuly 2025 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
IGC: CALMA trial nears completion and MINT-AD AI platform set for beta launch amid favorable regulations - TradingView
IGC: Alzheimer's drug trial nears completion as AI dementia tool readies for beta launch - TradingView
Is IGC Pharma Inc. stock a buy before product launchesJuly 2025 Movers & Long Hold Capital Preservation Tips - mfd.ru
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - GuruFocus
Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Finviz
Is IGC Pharma Inc. likely to announce a buybackJuly 2025 Market Mood & Daily Entry Point Alerts - mfd.ru
Inside an Alzheimer’s trial: IGC Pharma talks new drug and AI treatment push - Stock Titan
Aug Catalysts: Should I trade or invest in IGC Pharma IncJuly 2025 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Why IGC Pharma Inc. (IGS1) stock could rally stronglyJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - mfd.ru
IGC Pharma Announces Equity Research Update by Alliance Global Partners - BioSpace
IGC Pharma Announces Equity Research Update by Alliance Global P - GuruFocus
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - BioSpace
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier A - GuruFocus
IGC Pharma Expands Key Alzheimer's Trial into Colombia - GuruFocus
Colombia’s unique inherited Alzheimer’s community joins IGC drug trial - Stock Titan
Trade Report: Will IGC Pharma Inc benefit from green energy policiesWall Street Watch & Real-Time Buy Signal Notifications - baoquankhu1.vn
Trend Recap: Can IGC Pharma Inc ride the EV wave2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Treasury Yields: Is IGC Pharma Inc in a bullish channelJuly 2025 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Retail Trends: Can SUUN sustain earnings growth2025 Macro Impact & Weekly High Return Stock Forecasts - baoquankhu1.vn
Market Pulse: How volatile is ProShares Trust ProShares Short High Yield stockPortfolio Profit Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
Is IGC Pharma Inc. (IGS1) stock undervalued historicallyJuly 2025 Price Swings & AI Driven Price Forecasts - mfd.ru
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation - Weatherford Democrat
Forecast Cut: Is IGC Pharma Inc a cyclical or defensive stockJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
Setup Watch: Is IGC Pharma Inc a momentum stockJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Aug Breakouts: How does IGC Pharma Inc perform in inflationary periods2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Aug Volume: Should I buy SONY stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
IGC Pharma announces registered direct equity offering financing - MSN
IGC Pharma Expands Phase 2 CALMA Trial With New Clinical Trial Site at Integrative Clinical Trials in New York - 富途牛牛
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Finviz
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial S - GuruFocus
IGC Expands Alzheimer's Clinical Trial with New Site in Brooklyn - GuruFocus
IGC Pharma Inc (IGC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.71%
0.02%
자본화:
|
볼륨(24시간):